CD8+CD39+ T Cells Mediate Anti-Tumor Cytotoxicity in Bladder Cancer

Transcriptional Activity and Stability of CD39+CD103+CD8+ T Cells in Human High-Grade Endometrial Cancer

(2020) Hagma H. Workel et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

High Expression of CD39 is Associated with Poor Prognosis and Immune Infiltrates in Clear Cell Renal Cell Carcinoma

(2020) Jie Wu et al.   OncoTargets and Therapy

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.

(2019) Amod Sarnaik et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4

(2019) Jitske van den Bulk et al.   Genome Medicine

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

(2018) Daniela S. Thommen et al.   NATURE MEDICINE

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

(2018) Thomas Duhen et al.   Nature Communications

Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets

(2018) Ádám Nagy et al.   Scientific Reports

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

(2018) Yannick Simoni et al.   NATURE

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

(2017) Bertrand Allard et al.   IMMUNOLOGICAL REVIEWS

Unlocking bladder cancer

(2017) Chris Berdik   NATURE

GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses

(2017) Zefang Tang et al.   NUCLEIC ACIDS RESEARCH

UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses

(2017) Darshan S. Chandrashekar et al.   NEOPLASIA

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

(2016) Padmanee Sharma et al.   LANCET ONCOLOGY

Overexpression of CD39 in hepatocellular carcinoma is an independent indicator of poor outcome after radical resection

(2016) Xiao-Yan Cai et al.   MEDICINE

T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival

(2015) Meng Yang et al.   JOURNAL OF SURGICAL ONCOLOGY

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

(2015) Aaron P Rapoport et al.   NATURE MEDICINE

Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?

(2014) Inge Marie Svane et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

(2014) Alena Gros et al.   JOURNAL OF CLINICAL INVESTIGATION

Prognostic Value of T Cell Immunoglobulin Mucin-3 in Prostate Cancer

(2013) Yong-Rui Piao et al.   Asian Pacific Journal of Cancer Prevention

CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor

(2013) Q. Ye et al.   CLINICAL CANCER RESEARCH

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

(2011) S. A. Rosenberg et al.   CLINICAL CANCER RESEARCH

Signaling Through OX40 Enhances Antitumor Immunity

(2010) Shawn M. Jensen et al.   SEMINARS IN ONCOLOGY